SCHEMBL2484846

SCHEMBL2484846

COC(=O)C1CN(C(=O)O)CCC1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.37
CYP1A2 P05177 1/20 0.35
HIF1A Q16665 1/20 0.35
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
F2R P25116 1/20 0.34
ALDH1A1 P00352 1/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
TSHR P16473 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28926595 0.87 CHRNB2 (0.39) BRD4CYP1A2HIF1AITGB3ITGA2B
SCHEMBL2447519 0.87 BRD4 (0.37) BRD4CYP1A2HIF1AITGB3ITGA2B
SCHEMBL10359379 0.85 BRD4 (0.36) BRD4CYP1A2HIF1AITGB3ITGA2B
SCHEMBL15517095 0.83 BRD4 (0.39) BRD4CYP1A2HIF1AALDH1A1SLC6A2
SCHEMBL7293619 0.83 ITGB3 (0.37) BRD4ITGB3ITGA2BF2RALDH1A1
SCHEMBL2127522 0.83 MAPT (0.44) ALDH1A1CHRM2CHRM4CHRM5CHRM1
SCHEMBL17847640 0.81 TLR4 (0.34) BRD4ITGB3ITGA2BF2RNPC1
SCHEMBL31454859 0.81 ALDH1A1 (0.42) ALDH1A1TSHR
SCHEMBL9295029 0.81 KMT2A (0.46) CYP1A2HIF1AALDH1A1
SCHEMBL4718414 0.81 ITGB3 (0.33) ITGB3ITGA2BF2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3571198-B1 BICYCLIC AMINES AS JAK KINASE INHIBITORS LEO PHARMA AS (DK) 2023-02-01 EP disclosed
US-10851116-B2 Bicyclic amines as novel JAK kinase inhibitors LEO PHARMA A/S (DK) 2020-12-01 US disclosed
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 EP disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed
WO-2009049018-A1 NOVEL COMPOUNDS AND METHODS OF USING THEM SYNDAX PHARMACEUTICALS, INC. (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851116-B2 Bicyclic amines as novel JAK kinase inhibitors JAK1, JAK2, JAK3 BRD4 91/4885CYP1A2 1962/4885HIF1A 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.